Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the anti-T cell antibody, Thymoglobulin is a more effective induction medication than the anti-IL-2R inhibitor daclizumab, in kidney transplant recipients who have a positive crossmatch with their live donor.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Treatments: Daclizumab; Dexamethasone; Mycophenolic Acid; Prednisone; Tacrolimus; Thymoglobulin

Criteria

Inclusion Criteria:

• Adult (18 years or older)

• End-stage renal disease

• Identified to have positive lymphocytotoxic crossmatch or flow cytometric crossmatch with live donor

Exclusion Criteria:

• Deceased donor recipients

• Pregnancy

• Active infection

• History of cancer within the past two years (with the exception of non-melanomatous skin cancer)

• History of heparin induced thrombocytopenia

• Medical contraindications to transplant procedure